Pneumonia Vaccine Education Intervention Study

NCT06136832 | Completed

• 1 other identifier: 2023-1678
• Study Type: interventional
• Target: 141
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this interventional clinical trial is to investigate the impact of medicine and pharmacy-led education on patient acceptance rates of Prevnar 20 pneumonia vaccination in patients eligible to receive the vaccine. The education intervention and subsequent option to get the vaccine will be done while the patient is admitted to inpatient care, prior to discharge. The main questions the study aims to answer are:

• Will supplemental education about the Prevnar 20 Pneumococcal vaccine influence patient acceptance rates when given a decision to receive it?
• Is there any other statistically relevant qualitative reasoning behind the patient's final decision for accepting or refusing the vaccine?

Conditions

Pneumonia, Pneumococcal; Vaccine

Keywords

Vaccine; Pneumococcal; Education; Interventional; Acceptance; Pneumonia

Outcome Measures

Primary Outcomes (1)

• Number of patients accepting the Prevnar 20 Pneumococcal vaccine after receiving pharmacy-led education intervention during standard care.

  Patients answering "yes" when given the option to receive the Prevnar 20 Pneumococcal vaccine after they receive vaccine-specific education to increase their knowledge and awareness of the pneumonia vaccine.

  Through study completion of up to one year.

Study Arms (2)

Control

NO INTERVENTION

Patients randomized into this arm DO NOT RECEIVE Pneumococcal vaccine education prior to given the option to accept or refuse the vaccine.

Treatment

EXPERIMENTAL

Patients randomized into this arm RECEIVE Pneumococcal vaccine education prior to given the option to accept or refuse the vaccine.

Behavioral: Pneumococcal Vaccine Education

Interventions

Pneumococcal Vaccine Education BEHAVIORAL

Education provided to patients to inform them and increase their awareness on the benefits of getting vaccinated against Pneumococcal pneumonia

Also known as: Educational

Treatment

Eligibility Criteria

• Age: 18 Years - 64 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Patients admitted to inpatient Family Medicine service with Type I and II Diabetes.
• Patients who have not been previously vaccinated against pneumonia.
• Patients meeting specific eligibility for Prevnar 20 vaccine: Over age of 65 OR have been diagnosed with any of the following: diabetes, chronic obstructive pulmonary disease, or asthma.

You may not qualify if:

• Patients that already received pneumonia vaccination in care history.
• Patients with pneumonia inpatient diagnosis at time of recruitment.
• Patients with any active infections.
• Patients who are in an immunosuppressed status.
• Patients allergic to any components of the vaccine.

Sponsors & Collaborators

• Geisinger Clinic: lead

Study Sites (1)

Geisinger South Wilkes-Barre

Wilkes-Barre, Pennsylvania, 18702, United States

Location

Related Publications (9)

• Robke JT, Woods M. A decade of experience with an inpatient pneumococcal vaccination program. Am J Health Syst Pharm. 2010 Jan 15;67(2):148-52. doi: 10.2146/ajhp080638.

  PMID: 20065270 BACKGROUND

• Stinchfield PK. Practice-proven interventions to increase vaccination rates and broaden the immunization season. Am J Med. 2008 Jul;121(7 Suppl 2):S11-21. doi: 10.1016/j.amjmed.2008.05.003.

  PMID: 18589063 BACKGROUND

• Coyle CM, Currie BP. Improving the rates of inpatient pneumococcal vaccination: impact of standing orders versus computerized reminders to physicians. Infect Control Hosp Epidemiol. 2004 Nov;25(11):904-7. doi: 10.1086/502317.

  PMID: 15566021 BACKGROUND

• Rees S, Stevens L, Drayton J, Engledow N, Sanders J. Improving inpatient pneumococcal and influenza vaccination rates. J Nurs Care Qual. 2011 Oct-Dec;26(4):358-63. doi: 10.1097/NCQ.0b013e31821fb6bb.

  PMID: 21577146 BACKGROUND

• McFadden K, Seale H. A review of hospital-based interventions to improve inpatient influenza vaccination uptake for high-risk adults. Vaccine. 2021 Jan 22;39(4):658-666. doi: 10.1016/j.vaccine.2020.12.042. Epub 2020 Dec 21.

  PMID: 33357955 BACKGROUND

• Queeno BV. Evaluation of Inpatient Influenza and Pneumococcal Vaccination Acceptance Rates With Pharmacist Education. J Pharm Pract. 2017 Apr;30(2):202-208. doi: 10.1177/0897190016628963. Epub 2016 Jul 9.

  PMID: 26880320 BACKGROUND

• Cotugno S, Morrow G, Cooper C, Cabie M, Cohn S. Impact of pharmacist intervention on influenza vaccine assessment and documentation in hospitalized psychiatric patients. Am J Health Syst Pharm. 2017 Dec 1;74(23 Supplement 4):S90-S94. doi: 10.2146/ajhp160755.

  PMID: 29167145 BACKGROUND

• Ahmad Hamidi A, Gelmez Tas B, Gunduz A, Nur Celebi S, Esen ES, Toprak D, Dokmetas I. Immunization rates of pneumococcal, influenza and tetanus vaccines and knowledge and attitudes of adult patients who receive inpatient treatment at hospital: Point prevalence study. Hum Vaccin Immunother. 2018;14(11):2649-2653. doi: 10.1080/21645515.2018.1489187. Epub 2018 Jul 12.

  PMID: 29913102 BACKGROUND

• Dodds ES, Drew RH, May DB, et al. Impact of a Pharmacy Student-Based Inpatient Pneumococcal Vaccination Program. AJPE 2001;65.

  BACKGROUND

MeSH Terms

Conditions

Pneumonia, Pneumococcal; Pneumonia

Condition Hierarchy (Ancestors)

Pneumococcal Infections; Streptococcal Infections; Gram-Positive Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Infections; Pneumonia, Bacterial; Respiratory Tract Infections; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Jason Woloski, MD

  Geisinger Clinic

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Patients are randomized into either controls or treatments upon being determined eligible. Control group does not receive education intervention prior to asking if they would like the vaccine. Treatment group does receive education intervention prior to asking if they'd like the vaccine.

Study Record Dates

• First Submitted: November 8, 2023
• First Posted: November 18, 2023
• Study Start: May 6, 2024
• Primary Completion: January 26, 2025
• Study Completion: January 26, 2025
• Last Updated: July 8, 2025

Record last verified: 2025-07

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)